The dependence of chronic myeloid leukemia (CML) on the translocated BCR-ABL kinase is associated with unique drug responses to small molecule inhibitors [82]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.